For the Inventor, By the Inventor

Enter assignee name

Tübingen, Germany

Curevac Se

USPTO Granted Patents = 66

EPO Patents = 10

Trademarks = 10

Forward Citations = 143

Loading Chart...

Loading Chart...

58 inventors (with patents filed for the assignee):

Benjamin Petsch (30 out of 46 patents)

Susanne Rauch (17 out of 22 patents)

Thomas Kramps (13 out of 26 patents)

4. Tilmann Roos (10 out of 20 patents)

5. Margit Schnee (10 out of 21 patents)

6. Edith Jasny (10 out of 11 patents)

7. Thomas Schlake (9 out of 33 patents)

8. Benyamin Yazdan Panah (8 out of 16 patents)

9. Karl-Josef Kallen (8 out of 29 patents)

10. Hans Wolfgang Große (8 out of 11 patents)

11. Andreas Thess (7 out of 67 patents)

12. Daniel Voss (7 out of 12 patents)

13. Mariola Fotin-Mleczek (7 out of 27 patents)

14. Lothar Stitz (5 out of 11 patents)

15. Jochen Probst (5 out of 37 patents)

Core Competencies:

Nucleic Acid

mRNA Vaccines

Lipid Nanoparticles

CRISPR

Flavivirus Vaccine

Zika Virus Vaccine

RNA Analysis

Respiratory Syncytial Virus

Prostate Cancer

Norovirus Antigen

SARS-CoV-2 Variants

Combination Vaccines

66 patents: Sort by Forward Citations

1. 12649914 - METHOD OF RNA IN VITRO TRANSCRIPTION USING A BUFFER CONTAINING A DICARBOXYLIC ACID OR TRICARBOXYLIC ACID OR A SALT THEREOF (2026-06-09),

2. 12618060 - Nucleic acid molecules (2026-05-05),

3. 12589078 - LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS (2026-03-31),

4. 12569549 - Flavivirus vaccine (2026-03-10),

5. 12533422 - MODIFIED RNA WITH DECREASED IMMUNOSTIMULATORY PROPERTIES (2026-01-27),

6. 12527856 - Artificial RNA molecules encoding a norovirus antigen and uses thereof (2026-01-20),

7. 12514918 - Nucleic acid molecules and uses thereof (2026-01-06),

8. 12508308 - Influenza mRNA vaccines (2025-12-30),

9. 12496335 - Zika virus vaccine (2025-12-16),

10. 12492425 - METHODS FOR RNA ANALYSIS (2025-12-09),

11. 12460204 - Artificial nucleic acid molecules for improved protein or peptide expression (2025-11-04),

12. 12447209 - Combination of vaccination and inhibition of the PD-1 pathway (2025-10-21),

13. 12442005 - Artificial nucleic acid molecules for improved protein expression (2025-10-14),

14. 12397048 - Bunyavirales vaccine (2025-08-26),

15. 12390523 - Coronavirus vaccine (2025-08-19),

CureVac is a leading clinical-stage bio-pharmaceutical company that focuses on developing mRNA-based therapies and vaccines. They leverage their cutting-edge messenger RNA (mRNA) technology platform to develop innovative solutions for various diseases, including infectious diseases, cancer, and rare diseases. CureVac's mRNA technology enables them to potentially create personalized medicines and combat emerging pandemic threats, offering a promising approach to healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

66 Patents

#5 in Tübingen

#854 in Germany

#11,138 in the World

Tübingen, Germany

Curevac Se

Forward Citations = 143

58 inventors:

Benjamin Petsch (30 out of 46 patents)

Susanne Rauch (17 out of 22 patents)

Thomas Kramps (13 out of 26 patents)

4. Tilmann Roos (10 out of 20 patents)

5. Margit Schnee (10 out of 21 patents)

Please report any incorrect information to [email protected]

Loading…